ReproCELL Acquires Stemgent’s iPSC Business
ReproCELL acquired the business for $8.5 million in cash, according to a Google translation of a ReproCELL announcement. A spokesperson for ReproCELL told IBO, “Stemgent is a recognized leader in RNA reprogramming technology for efficiently generating primary iPS cells that are virus free.”
Yokohama, Japan 9/9/14—Publicly held Japanese iPSC firm ReproCELL has acquired the iPS Cell Business Unit of Stemgent for an undisclosed amount. The Business Unit supplies iPSC-research reagent products, including mRNA reprogramming kits, xeno-free culture media and specialty chemicals for cell differentiation. ReproCELL stated that the acquisition would broaden its selection of iPSC products and strengthen its US sales and marketing channel. The company also stated that the business’s scientific advisory board will give it a US academic network.
